In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

The stock’s decline was notably more severe than that of its partner, Sanofi (NASDAQ:SNY), which experienced a 6% drop. Bernstein SocGen analysts highlighted concerns about Regeneron’s ability ...

The decision follows recent challenges faced by the company, including the failure of itepekimab and ongoing issues ... stock decline, but analysts still see long-term value in Regeneron’s ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities.

could shift investor focus away from concerns over the erosion of Eylea, another of Regeneron’s products. This shift could potentially lead to an appreciation in stock value, aligning it more closely ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculation, trading at an attractive P/E ratio of 14.36. For deeper insights into Regeneron’s valuation and ...

Discover analysts' top stock upgrades, downgrades, and key market insights, featuring Nvidia, Southwest Airlines, Salesforce, ...

The S&P 500 slipped 0.4% on Tuesday, May 20, snapping a six-day winning streak as investors' confidence on trade and inflation appeared to waver.